Pirfenidone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pirfenidone: From Idiopathic Pulmonary Fibrosis to Extracutaneous Mastocytoma
One-Sentence Summary
Pirfenidone is an antifibrotic agent (its documented mechanism targets TGF-β signalling and fibroblast proliferation); this evidence pack does not contain a structured original-indication record, but pirfenidone is internationally recognised for idiopathic pulmonary fibrosis. The TxGNN model’s top-ranked prediction for this drug is Extracutaneous Mastocytoma, but this signal is currently supported by zero clinical trials and zero publications — it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no ARTG licences or original_indications records returned). Pirfenidone is widely known as an antifibrotic used for idiopathic pulmonary fibrosis — noted here as general background, not sourced from this pack |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 (model prediction only — no trials, no literature) |
| Australia Market Status | Not currently marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not populated in this evidence pack (original_moa is a data gap). However, the model’s own rationale text describes pirfenidone’s known action as inhibition of TGF-β signalling and fibroblast proliferation — consistent with its established antifibrotic use.
Extracutaneous mastocytoma is pathologically driven by KIT-mutation-related mast cell proliferation, a mechanism that does not overlap with TGF-β/fibroblast pathways. The evidence pack’s own mechanistic assessment for this candidate states there is “no known intersection” between pirfenidone’s fibroblast-inhibitory action and mast-cell-driven pathology, and explicitly characterises the link as speculative with no supporting evidence. In other words, this is the highest-scoring candidate by TxGNN’s topological similarity metric, but the model score is not corroborated by a plausible mechanism or by any external evidence.
For context, one lower-ranked candidate in this pack (fibroblastic neoplasm, rank 9) has a mechanistically more coherent rationale and six supporting publications — but that literature also contains case reports of pirfenidone-associated sarcoma development and dermatofibroma aggravation, a safety signal worth carrying forward regardless of which indication is pursued (see Safety Considerations below).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries were returned for this drug in the evidence pack (total_licenses = 0, market status: not currently marketed). No product/dosage-form information is available to tabulate.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information — this evidence pack’s key_warnings, contraindications, and drug-interaction (DDI) fields are all unpopulated (DDI query status: not found).
Additional signal from literature (not PI-sourced): publications surfaced under a different candidate indication in this same evidence pack (fibroblastic neoplasm, rank 9) include two case reports of concern — multiple eruptive dermatofibromas aggravated by pirfenidone in a systemic sclerosis patient (PMID 32572469), and undifferentiated pleomorphic sarcoma following pirfenidone use (PMID 29702057). These suggest pirfenidone’s effect on fibroblastic/mesenchymal tissue may be bidirectional rather than uniformly antiproliferative, and should be flagged for any mesenchymal-lineage repurposing pathway, including mastocytoma if pursued.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5, model-only signal: no clinical trials, no literature, and the model’s own mechanistic rationale finds no credible link between pirfenidone’s known TGF-β/fibroblast pathway and the KIT-driven pathology of extracutaneous mastocytoma. Combined with the drug’s non-marketed status in Australia and a blocking gap in TFDA/PI safety data (DG001), there is no basis to advance this candidate beyond a research hypothesis.
To proceed, the following is needed:
- TGA-approved Product Information for pirfenidone (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism-of-action data from DrugBank (DG002)
- Preclinical or mechanistic studies directly linking pirfenidone to mast cell biology or KIT-pathway modulation
- If mesenchymal/fibroblastic-lineage indications are explored instead, dedicated review of the sarcoma-induction and dermatofibroma-aggravation case reports noted above before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.